连续两日股价大跌 信邦制药涉嫌单位行贿罪被起诉

Core Viewpoint - The company, Xinbang Pharmaceutical, is facing significant legal challenges due to allegations of unit bribery, which has led to a sharp decline in its stock price and market value [1][2]. Group 1: Legal Issues - Xinbang Pharmaceutical has been accused of unit bribery, with the prosecution receiving materials from the supervisory committee for the case [2]. - The former chairman, An Huailue, and the key subsidiary, Keke Pharmaceutical, are implicated in the bribery case, raising concerns about the company's governance and operational integrity [3][4]. - If found guilty, the company could face fines and additional legal responsibilities, including potential civil compensation to affected investors [2][3]. Group 2: Financial Performance - The company is experiencing a downturn in financial performance, with a reported revenue of 42.66 billion yuan for the first three quarters of 2025, a decrease of 6.55% year-on-year, and a net profit of 1.52 billion yuan, down 13.74% [7]. - Keke Pharmaceutical, a core subsidiary, contributed significantly to Xinbang's financials, with revenues of 2.278 billion yuan and net profits of 94.5 million yuan in 2023, accounting for 35.26% and 26.71% of Xinbang's total revenue and net profit, respectively [3]. Group 3: Corporate Governance - An Huailue, the former chairman, has a history of involvement in the company's operations, including the acquisition of Keke Pharmaceutical, which is now under scrutiny due to the bribery allegations [5][6]. - The acquisition of Keke Pharmaceutical in 2013 was valued at approximately 997 million yuan, with a significant increase in asset valuation, raising questions about the legitimacy of the transaction [5][6].